Loading
companiesCompany
Treeline Biosciences
Treeline Biosciences is a well-funded private company building cancer drugs of several kinds, including a pill that blocks all forms of the KRAS cancer protein and drugs for lymphoma.
Overview
Treeline Biosciences is a privately held, Watertown, Massachusetts biopharmaceutical company founded in 2021 that combines in-house inhibitor, protein degrader and antibody-drug conjugate capabilities with computational and machine-learning models. Its clinical programmes are TLN-121, a BCL6 degrader in phase 1 for B-cell and T-cell lymphomas; TLN-254, an EZH2 inhibitor (zeprumetostat, SHR2554) in-licensed from Jiangsu Hengrui for territories outside Greater China and in phase 1 in peripheral and cutaneous T-cell lymphoma; and TLN-372, a pan-KRAS inhibitor in phase 1 in solid tumours. Preclinical work extends to immunology and neurology. SEC Form D filings show more than 1 billion US dollars sold across private offerings between 2021 and 2025.
Headquarters
Watertown, MA, US
Funding
All startupsGrowth stage
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Form D offering · Total sold of a 250 million US dollar offering per Form D filed September 2025 | 2025 | $200M | sec.gov |
| Form D offering · Total sold per Form D filed October 2024 | 2024 | $422M | sec.gov |
| Form D offering · Total sold per Form D filed October 2022 | 2022 | $261M | sec.gov |
| Form D offering · Total sold per Form D filed April 2021 | 2021 | $212M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Founded
2021
Notes
top- The domain treelinebio.com does not resolve; the company site is treeline.bio. Round names and investors are not disclosed in the Form D filings or on the site. The dlbcl tag is an approximation for 'B-cell and T-cell lymphomas'.
Similar pages
- PersonKristian Helin
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- IdeaBlock the chemical switch that lets cells hide from treatment
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- CompanyProxygen
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- CompanyPrelude Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- TrialGOLSEEK-1
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
- IdeaAn open degrader consortium against every undruggable driver transcription factor
Shares AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation), KRAS.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
- CompanyKumquat Biosciences
Shares KRAS & RAS inhibitors, KRAS.